Brian Weinstein
Stock Analyst at William Blair
(0.40)
# 4,110
Out of 4,944 analysts
11
Total ratings
33.33%
Success rate
-19.18%
Average return
Main Sectors:
Stocks Rated by Brian Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDSX Biodesix | Downgrades: Market Perform | n/a | $0.38 | - | 2 | May 14, 2025 | |
| BDX Becton, Dickinson and Company | Downgrades: Market Perform | n/a | $195.96 | - | 1 | May 1, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | n/a | $13.57 | - | 2 | Jul 15, 2022 | |
| GKOS Glaukos | Upgrades: Outperform | n/a | $91.79 | - | 3 | Feb 3, 2022 | |
| SERA Sera Prognostics | Initiates: Outperform | n/a | $2.30 | - | 1 | Aug 9, 2021 | |
| QDEL QuidelOrtho | Upgrades: Outperform | n/a | $27.08 | - | 2 | Jul 18, 2017 |
Biodesix
May 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Becton, Dickinson and Company
May 1, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $195.96
Upside: -
10x Genomics
Jul 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $13.57
Upside: -
Glaukos
Feb 3, 2022
Upgrades: Outperform
Price Target: n/a
Current: $91.79
Upside: -
Sera Prognostics
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.30
Upside: -
QuidelOrtho
Jul 18, 2017
Upgrades: Outperform
Price Target: n/a
Current: $27.08
Upside: -